CUOMO, ONOFRIO
 Distribuzione geografica
Continente #
NA - Nord America 117
EU - Europa 107
AS - Asia 71
SA - Sud America 34
AF - Africa 3
Totale 332
Nazione #
US - Stati Uniti d'America 113
IT - Italia 65
SG - Singapore 36
BR - Brasile 28
DE - Germania 12
VN - Vietnam 11
CN - Cina 10
IN - India 8
FI - Finlandia 7
NL - Olanda 6
GB - Regno Unito 5
AR - Argentina 3
SE - Svezia 3
CA - Canada 2
CZ - Repubblica Ceca 2
RU - Federazione Russa 2
BD - Bangladesh 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
FR - Francia 1
ID - Indonesia 1
IE - Irlanda 1
IQ - Iraq 1
IR - Iran 1
LB - Libano 1
MA - Marocco 1
MX - Messico 1
PL - Polonia 1
PY - Paraguay 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 332
Città #
Dallas 17
Chandler 16
Singapore 15
Carbonia 12
Munich 11
Chicago 10
Ashburn 8
Ho Chi Minh City 7
Bengaluru 5
Hefei 5
London 5
Turku 5
Ercolano 4
Santa Clara 4
Hanoi 3
Lawrence 3
Paola 3
Princeton 3
Rome 3
Afragola 2
Delhi 2
Gesuiti 2
Helsinki 2
Olomouc 2
Porto Alegre 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
Alvorada 1
Balıkesir 1
Barra de São Francisco 1
Baturité 1
Beirut 1
Benevento 1
Biên Hòa 1
Boardman 1
Bragança Paulista 1
Brasília 1
Caicó 1
Chaguanas 1
Charlotte 1
Chortkiv 1
Ciudad del Este 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Dublin 1
Ezeiza 1
Guarulhos 1
Indian Trail 1
Isidro Casanova 1
Jacarezinho 1
Jinhua 1
Johannesburg 1
Lajeado 1
Manaus 1
Memphis 1
Milan 1
Montreal 1
Mosul 1
Naples 1
New Delhi 1
Niterói 1
Norwich 1
Nova Iguaçu 1
Nuremberg 1
Osasco 1
Padang 1
Palermo 1
Petrópolis 1
Pilar 1
Pittsburgh 1
Ponto Belo 1
Rio de Janeiro 1
San Francisco 1
Santo Antônio do Monte 1
Satuba 1
Seattle 1
Sorocaba 1
St Petersburg 1
Stockholm 1
São José do Rio Preto 1
Taubaté 1
Tizi Ouzou 1
Torres 1
Ubá 1
Votuporanga 1
Warsaw 1
Wilmington 1
Zipaquirá 1
Totale 220
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 96
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 78
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 61
The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion 55
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 55
Totale 345
Categoria #
all - tutte 2.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.270


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202219 0 0 0 1 1 0 1 1 9 6 0 0
2022/202346 6 6 1 2 7 4 0 3 9 3 3 2
2023/202443 19 4 4 1 2 7 0 0 0 0 3 3
2024/2025124 7 3 1 5 8 14 6 3 10 2 32 33
2025/2026112 13 17 34 29 19 0 0 0 0 0 0 0
Totale 345